Deciphering the neuroprotective signaling of SGLT2 inhibitors in Alzheimer's disease
Journal of Alzheimer’s Disease · 30.10.2026
DOI: 10.1177/13872877261502860 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 30.10.2026. Verfasst von Takahiro Kamihara und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, National Center for Geriatrics and Gerontology, Obu, Japan. Die Arbeit nennt 42 Literaturangaben. Gefördert von: The grants from the Research Funding of Longevity Sciences from the National Center for Geriatrics and Gerontology, Japan Society for the Promotion of Science.
Themen: Demenz
Abstract (Originalsprache)
Background
Alzheimer's disease (AD) currently lacks fundamental curative treatments. While epidemiological evidence increasingly links sodium-glucose cotransporter 2 (SGLT2) inhibitors to reduced AD risk, the underlying molecular mechanisms remain poorly understood.
Objective
This study aimed to elucidate the potential molecular pathways through which SGLT2 inhibitors intervene in AD pathophysiology using a bioinformatics approach.
Methods
Potential targets for empagliflozin and dapagliflozin were predicted via SwissTargetPrediction. AD-related differentially expressed genes (DEGs) were identified from a human brain dataset (GSE125583) utilizing the GREIN platform. Common genes were analyzed for functional networks (GeneMANIA/STRING) and pathway enrichment (KEGG). Hub proteins were identified using Cytoscape centrality metrics, and organ-specific expression was verified through the RefEx database.
Results
Fifty-seven genes were common to SGLT2 inhibitor targets and AD DEGs. Notably, the transporters SLC5A11 and SLC2A1 were significantly upregulated in AD brains and exhibited high brain-specific expression. Pathway analysis revealed significant involvement in the MAPK and FoxO signaling pathways, which regulate apoptosis, autophagy, and oxidative stress. Key hub proteins identified included ERBB2, HSP90AA1, DPP4, and SLC2A1. It is hypothesized that SGLT2 inhibitors exert neuroprotective effects by targeting these upregulated transporters, thereby suppressing MAPK signaling and activating the FoxO pathway.
Conclusions
Our findings suggest that SGLT2 inhibitors may normalize MAPK/FoxO signaling and restore cellular homeostasis in the AD brain. This study provides a potential theoretical insight for the drug repositioning of antidiabetic agents and offers key indicators for the design of future clinical and basic research in AD therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, National Center for Geriatrics and Gerontology, Obu, Japan.
- Graduate School of International Social Sciences, Yokohama National University, Yokohama, Japan.
- Support and Research Center, Tokyo Gakugei University, Tokyo, Japan.
- Department of Cardiology, Toyota Kosei Hospital, Toyota, Japan.
- Department of Metabolic Research, National Center for Geriatrics and Gerontology, Obu, Japan.
ORCID-Profile: Takahiro Kamihara, Takuya Omura
Förderung
- The grants from the Research Funding of Longevity Sciences from the National Center for Geriatrics and Gerontology
- Japan Society for the Promotion of Science
Zitieren
APA
Kamihara, T., Kato, R., Morisaki, A., Kaneko, S., Omura, T., & Shimizu, A. (2026). Deciphering the neuroprotective signaling of SGLT2 inhibitors in Alzheimer's disease. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877261502860
Vancouver
Kamihara T, Kato R, Morisaki A, Kaneko S, Omura T, Shimizu A. Deciphering the neuroprotective signaling of SGLT2 inhibitors in Alzheimer's disease. Journal of Alzheimer’s Disease. 2026. doi:10.1177/13872877261502860
BibTeX
@article{Kamihara2026,
author = {Kamihara, Takahiro and Kato, Ryutah and Morisaki, Akira and Kaneko, Shinji and Omura, Takuya and Shimizu, Atsuya},
title = {Deciphering the neuroprotective signaling of SGLT2 inhibitors in Alzheimer's disease},
journal = {Journal of Alzheimer’s Disease},
year = {2026},
doi = {10.1177/13872877261502860}
}
EUVIMED